US 10,376,590 B2
Sustained delivery formulations of risperidone compound
Eric Dadey, Sevierville, TN (US); Qi Li, Fort Collins, CO (US); and Christopher Lindemann, Fort Collins, CO (US)
Assigned to INDIVIOR UK LIMITED, Hull (GB)
Filed by INDIVIOR UK LIMITED, Slough (GB)
Filed on Dec. 29, 2017, as Appl. No. 15/858,525.
Application 15/858,525 is a continuation of application No. 12/602,058, granted, now 10,010,612, previously published as PCT/US2008/001928, filed on Feb. 13, 2008.
Claims priority of provisional application 60/940,340, filed on May 25, 2007.
Prior Publication US 2018/0154001 A1, Jun. 7, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/34 (2017.01); A61K 9/00 (2006.01); A61K 31/51 (2006.01); A61K 47/22 (2006.01); A61K 47/32 (2006.01); A61K 31/519 (2006.01)
CPC A61K 47/34 (2013.01) [A61K 9/0024 (2013.01); A61K 31/519 (2013.01); A61K 47/22 (2013.01); A61K 47/32 (2013.01)] 45 Claims
 
1. A method of treating schizophrenia in a subject in need thereof, the method comprising subcutaneously injecting the subject with a composition comprising risperidone base in a solution comprising: (i) an 80/20 poly(DL-lactide-co-glycolide) copolymer having a carboxy terminal group, and (ii) N-methyl-2-pyrrolidone; to treat the schizophrenia.